Postmenopausal women with osteoporosis who received a single infusion of zoledronate after 2 to 5 years of denosumab therapy retained more than half of bone mineral density gained before stopping ...

Please provide your email address to receive an email when new articles are posted on . Researchers calculated the likelihood of achieving a BMD T-score of –2.5 or higher with denosumab based on ...